Agile Therapeutics Inc (AGRX)

0.37 0.00 (0.00%) USD  |  OTCM  |  Apr 18, 15:56
More

Agile Therapeutics Research and Development Expense (Quarterly): 0.054M for Dec. 31, 2023

Research and Development Expense (Quarterly) Chart

Historical Research and Development Expense (Quarterly) Data

View and export this data back to 2013. Upgrade now.
Date Value
December 31, 2023 0.054M
September 30, 2023 0.705M
June 30, 2023 0.703M
March 31, 2023 0.763M
December 31, 2022 0.352M
September 30, 2022 0.788M
June 30, 2022 0.856M
March 31, 2022 1.257M
December 31, 2021 1.678M
September 30, 2021 1.593M
June 30, 2021 0.862M
March 31, 2021 2.123M
December 31, 2020 3.012M
September 30, 2020 3.663M
June 30, 2020 3.661M
March 31, 2020 3.164M
December 31, 2019 2.837M
September 30, 2019 2.361M
June 30, 2019 1.779M
March 31, 2019 2.881M
December 31, 2018 1.856M
September 30, 2018 1.549M
Date Value
June 30, 2018 2.413M
March 31, 2018 3.96M
December 31, 2017 2.734M
September 30, 2017 3.175M
June 30, 2017 3.798M
March 31, 2017 4.721M
December 31, 2016 5.514M
September 30, 2016 4.911M
June 30, 2016 5.577M
March 31, 2016 4.927M
December 31, 2015 6.913M
September 30, 2015 7.162M
June 30, 2015 6.168M
March 31, 2015 5.378M
December 31, 2014 4.977M
September 30, 2014 4.602M
June 30, 2014 2.391M
March 31, 2014 1.394M
December 31, 2013 1.259M
September 30, 2013 2.398M
June 30, 2013 2.426M
March 31, 2013 3.072M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

0.054M
Minimum
Dec 2023
3.663M
Maximum
Sep 2020
1.695M
Average
1.593M
Median
Sep 2021

Research and Development Expense (Quarterly) Benchmarks

Altimmune Inc 16.91M
iBio Inc 1.535M
Ampio Pharmaceuticals Inc 1.242M
Oragenics Inc 11.04M
Actinium Pharmaceuticals Inc 8.118M